These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 34771558)

  • 1. Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions.
    Sflomos G; Schipper K; Koorman T; Fitzpatrick A; Oesterreich S; Lee AV; Jonkers J; Brunton VG; Christgen M; Isacke C; Derksen PWB; Brisken C
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer.
    Pramod N; Nigam A; Basree M; Mawalkar R; Mehra S; Shinde N; Tozbikian G; Williams N; Majumder S; Ramaswamy B
    Oncologist; 2021 Jun; 26(6):e943-e953. PubMed ID: 33641217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
    Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
    Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimized Modeling of Metastatic Triple-Negative Invasive Lobular Breast Carcinoma.
    Sflomos G; Schaumann N; Christgen M; Christgen H; Bartels S; Kreipe H; Battista L; Brisken C
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma.
    Christgen M; Kandt LD; Antonopoulos W; Bartels S; Van Bockstal MR; Bredt M; Brito MJ; Christgen H; Colpaert C; Cserni B; Cserni G; Daemmrich ME; Danebrock R; Dedeurwaerdere F; van Deurzen CH; Erber R; Fathke C; Feist H; Fiche M; Gonzalez CA; Ter Hoeve ND; Kooreman L; Krech T; Kristiansen G; Kulka J; Laenger F; Lafos M; Lehmann U; Martin-Martinez MD; Mueller S; Pelz E; Raap M; Ravarino A; Reineke-Plaass T; Schaumann N; Schelfhout AM; De Schepper M; Schlue J; Van de Vijver K; Waelput W; Wellmann A; Graeser M; Gluz O; Kuemmel S; Nitz U; Harbeck N; Desmedt C; Floris G; Derksen PW; van Diest PJ; Vincent-Salomon A; Kreipe H
    J Pathol Clin Res; 2022 Mar; 8(2):191-205. PubMed ID: 34889530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer.
    Du T; Sikora MJ; Levine KM; Tasdemir N; Riggins RB; Wendell SG; Van Houten B; Oesterreich S
    Breast Cancer Res; 2018 Sep; 20(1):106. PubMed ID: 30180878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinoma.
    Nakagawa S; Miyashita M; Maeda I; Goda A; Tada H; Amari M; Kojima Y; Tsugawa K; Ohi Y; Sagara Y; Sato M; Ebata A; Harada-Shoji N; Suzuki T; Nakanishi M; Ohta T; Ishida T
    Breast Cancer Res Treat; 2024 Apr; 204(3):453-463. PubMed ID: 38180699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
    Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic predisposition to in situ and invasive lobular carcinoma of the breast.
    Sawyer E; Roylance R; Petridis C; Brook MN; Nowinski S; Papouli E; Fletcher O; Pinder S; Hanby A; Kohut K; Gorman P; Caneppele M; Peto J; Dos Santos Silva I; Johnson N; Swann R; Dwek M; Perkins KA; Gillett C; Houlston R; Ross G; De Ieso P; Southey MC; Hopper JL; Provenzano E; Apicella C; Wesseling J; Cornelissen S; Keeman R; Fasching PA; Jud SM; Ekici AB; Beckmann MW; Kerin MJ; Marme F; Schneeweiss A; Sohn C; Burwinkel B; Guénel P; Truong T; Laurent-Puig P; Kerbrat P; Bojesen SE; Nordestgaard BG; Nielsen SF; Flyger H; Milne RL; Perez JI; Menéndez P; Benitez J; Brenner H; Dieffenbach AK; Arndt V; Stegmaier C; Meindl A; Lichtner P; Schmutzler RK; Lochmann M; Brauch H; Fischer HP; Ko YD; ; Nevanlinna H; Muranen TA; Aittomäki K; Blomqvist C; Bogdanova NV; Dörk T; Lindblom A; Margolin S; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Chenevix-Trench G; ; Lambrechts D; Weltens C; Van Limbergen E; Hatse S; Chang-Claude J; Rudolph A; Seibold P; Flesch-Janys D; Radice P; Peterlongo P; Bonanni B; Volorio S; Giles GG; Severi G; Baglietto L; McLean CA; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Simard J; Goldberg MS; Labrèche F; Dumont M; Kristensen V; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Kauppila S; Andrulis IL; Knight JA; Glendon G; Mulligan AM; Devillee P; Tollenaar RA; Seynaeve CM; Kriege M; Figueroa J; Chanock SJ; Sherman ME; Hooning MJ; Hollestelle A; van den Ouweland AM; van Deurzen CH; Li J; Czene K; Humphreys K; Cox A; Cross SS; Reed MW; Shah M; Jakubowska A; Lubinski J; Jaworska-Bieniek K; Durda K; Swerdlow A; Ashworth A; Orr N; Schoemaker M; Couch FJ; Hallberg E; González-Neira A; Pita G; Alonso MR; Tessier DC; Vincent D; Bacot F; Bolla MK; Wang Q; Dennis J; Michailidou K; Dunning AM; Hall P; Easton D; Pharoah P; Schmidt MK; Tomlinson I; Garcia-Closas M
    PLoS Genet; 2014 Apr; 10(4):e1004285. PubMed ID: 24743323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
    Zhao H
    Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer.
    De Schepper M; Vincent-Salomon A; Christgen M; Van Baelen K; Richard F; Tsuda H; Kurozumi S; Brito MJ; Cserni G; Schnitt S; Larsimont D; Kulka J; Fernandez PL; Rodríguez-Martínez P; Olivar AA; Melendez C; Van Bockstal M; Kovacs A; Varga Z; Wesseling J; Bhargava R; Boström P; Franchet C; Zambuko B; Matute G; Mueller S; Berghian A; Rakha E; van Diest PJ; Oesterreich S; Derksen PWB; Floris G; Desmedt C
    Mod Pathol; 2022 Dec; 35(12):1812-1820. PubMed ID: 35922548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unlocking the Mysteries of Lobular Breast Cancer Biology Needs the Right Combination of Preclinical Models.
    Bahnassy S; Sikora MJ; Riggins RB
    Mol Cancer Res; 2022 Jun; 20(6):837-840. PubMed ID: 35276005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.
    Sikora MJ; Cooper KL; Bahreini A; Luthra S; Wang G; Chandran UR; Davidson NE; Dabbs DJ; Welm AL; Oesterreich S
    Cancer Res; 2014 Mar; 74(5):1463-74. PubMed ID: 24425047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axillary lymph node status and invasive lobular breast cancer : Analysis of the Clinical Tumor Register of the AGO Austria.
    Danzinger S; Pöckl K; Kronawetter G; Pfeifer C; Behrendt S; Gscheidlinger P; Harrasser L; Mühlböck H; Dirschlmayer W; Schauer C; Reitsamer R; Uher H; Schönau K; Delmarko I; Singer CF
    Wien Klin Wochenschr; 2023 Sep; 135(17-18):463-471. PubMed ID: 37010596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
    Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
    Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive lobular carcinoma of the breast: patient response to systemic endocrine therapy and hormone response in model systems.
    Sikora MJ; Jankowitz RC; Dabbs DJ; Oesterreich S
    Steroids; 2013 Jun; 78(6):568-75. PubMed ID: 23178159
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Desmedt C; Pingitore J; Rothé F; Marchio C; Clatot F; Rouas G; Richard F; Bertucci F; Mariani O; Galant C; Fribbens C; O'Leary B; van den Eynden G; Salgado R; Turner NC; Piccart M; Vincent-Salomon A; Pruneri G; Larsimont D; Sotiriou C
    NPJ Breast Cancer; 2019; 5():9. PubMed ID: 30820448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast.
    Sottnik JL; Bordeaux EK; Mehrotra S; Ferrara SE; Goodspeed AE; Costello JC; Sikora MJ
    Mol Cancer Res; 2021 Aug; 19(8):1270-1282. PubMed ID: 33947745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
    Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
    Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.